Elsevier

Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series

Hewa Artin, Sean Bentley, Eamonn Mehaffey, Fred X. Liu, Kevin Sojourner, Andrew W. Bismark, David Printz, Ellen E. Lee, Brian Martis, Sharon De Peralta, Dewleen G. Baker, Jyoti Mishra, Dhakshin Ramanathan Published 6 May 2022 | https://doi.org/10.1016/j.eclinm.2022.101439 Abstract Background (S)-ketamine is a glutamatergic drug with potent and rapid acting effects for the treatment of depression. […]

Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series Read More »

Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder

C. Sophia Albott, Kelvin O. Lim, Christopher Erbes, Paul Thuras, Joseph Wels, Susanna J.Tye, Paulo R. Shiroma Published 14 April 2022 | https://doi.org/10.1016/j.jad.2022.04.066 Abstract Background The glutamate N-methyl-d-aspartate (NMDA) receptor antagonist ketamine rapidly ameliorates posttraumatic stress disorder (PTSD) and depression symptoms in individuals with comorbid PTSD and major depressive disorder (MDD). However, concerns over ketamine’s

Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder Read More »

The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research

Hartej Gill, Barjot Gill, Nelson B. Rodrigues, Orly Lipsitz, Joshua Daniel Rosenblat, Sabine El-Halabi, Flora Nasri, Rodrigo B. Mansur, Yena Lee, Roger S. McIntyre Published 23 November 2020 | https://doi.org/10.1016/j.neubiorev.2020.11.020 Abstract Replicated evidence has documented cognitive deficits in populations with treatment-resistant depression (TRD). Approximately 40 % of patients with MDD present with impairment of one

The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research Read More »

Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies

Camilla Crisanti, Paolo Enrico, Alessio Fiorentini, Giuseppe Delvecchio, Paolo Brambilla Published 29 July 2020 |  https://doi.org/10.1016/j.jad.2020.07.119 Abstract Background Most recent evidence support a rapid and sustained antidepressant effect of subanesthetic dose of intravenous ketamine in patients with major depressive disorder (MDD). However, clinical and animal studies investigating the effects of intravenous ketamine on specific functional

Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies Read More »

The emergence of ketamine as a novel treatment for posttraumatic stress disorder

Adriana Feder, Sarah B. Rutter, Daniela Schiller, Dennis S.Charney Published 19 June 2020 | https://doi.org/10.1016/bs.apha.2020.05.004 Abstract A serious lack of effective pharmacotherapeutic interventions for posttraumatic stress disorder (PTSD) raises the urgent need for the development of novel treatments. Ketamine—a noncompetitive glutamate N-methyl-d-aspartate (NMDA) receptor antagonist in use for decades as an anesthetic and analgesic agent—has

The emergence of ketamine as a novel treatment for posttraumatic stress disorder Read More »

Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression

Elia E. Acevedo-Diaz, Grace W. Cavanaugh, Dede Greenstein, Christoph Kraus, Bashkim Kadriu, Carlos A. Zarate, Lawrence T. Park Published 10 November 2019 | https://doi.org/10.1016/j.jad.2019.11.028 Abstract Background: Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects. This study sought to comprehensively assess side effects (SEs) associated with a single subanesthetic-dose

Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression Read More »

Scroll to Top